ENRIGHT PATRICK G 4
4 · Zenas BioPharma, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Zenas BioPharma (ZBIO) Director Patrick Enright Receives 18,500-Share Option Award
What Happened Patrick G. Enright, a director of Zenas BioPharma (ZBIO), received a derivative award (an option) covering 18,500 shares on June 15, 2026. The Form 4 reports the grant with a reported price of $0.00 (the filing shows an awarded option rather than an open-market purchase or sale). No cash changed hands at grant.
Key Details
- Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (timely filing).
- Instrument: Derivative—option award for 18,500 shares (reported as grant/award).
- Reported price/value: $0.00 on the Form 4 (typical for option grants; not an open-market purchase).
- Vesting: 100% vests on June 15, 2027 (one-year cliff), subject to continued service (footnote F1).
- Shares owned after the transaction: Not specified in the provided filing excerpt.
- No indication of sale, exercise, tax withholding, or 10b5-1 plan in this filing.
Context This is a time‑based option grant to a director that does not involve an immediate market purchase or sale. The option vests in full one year after the grant; only upon vesting and any subsequent exercise or sale would there be a reportable purchase or sale affecting share count or value. Grants are common as compensation and do not by themselves indicate trading sentiment.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-15+18,500→ 18,500 totalExercise: $18.71Exp: 2036-06-15→ Common Stock (18,500 underlying)
Footnotes (1)
- [F1]The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.